Tg Therapeutics, Inc.NASDAQ: TGTX

TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

· Issued by Tg Therapeutics, Inc.
Watch Tg Therapeutics explain itTG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call · Replay · Aug 3

UNITY-CLL trial met the primary endpoint of improved progression-free survival (PFS) (p

Company analysis